European Journal of Medical Research (Feb 2023)

Minimal-access video-assisted retroperitoneal and/or transperitoneal debridement (VARTD) in the management of infected walled-off pancreatic necrosis with deep extension: initial experience from a prospective single-arm study

  • Wanjie Wei,
  • Yongliang Tang,
  • Zuxiang Peng,
  • Jun Xie,
  • Zhaoxia Deng,
  • Tao Yuan,
  • Chun Tang,
  • Ruxian Pi,
  • Shunan Wang,
  • Siqi Zhao,
  • Lu Wang,
  • Chunxue Li,
  • Yaoli Wang,
  • Peng Zhang,
  • Zhengbin Wu,
  • Yafeng Wan,
  • Yan Ma,
  • Wen Tang,
  • Xianchun Liang,
  • Kun Liu,
  • Wei Wang,
  • Xianyi Liang,
  • Dongmei Zeng,
  • Shan Li,
  • Hongming Liu

DOI
https://doi.org/10.1186/s40001-023-01030-9
Journal volume & issue
Vol. 28, no. 1
pp. 1 – 11

Abstract

Read online

Abstract Background The currently preferred minimally invasive approaches have substantially improved outcomes of infected walled-off pancreatic necrosis (iWON). However, iWON with deep extension (iWONde) still poses a tricky challenge for sufficient necrosis evacuation by one stand-alone approach, often requiring repeated interventions. The aim of this study was to assess the effectiveness and safety of a minimal-access video-assisted retroperitoneal and/or transperitoneal debridement (hereafter called VARTD) in the management of iWONde. Methods Patients who had developed an iWONde were recruited to receive the VARTD in this prospective single-arm study. The primary efficacy endpoint was clinical improvement up to day 28 after the VARTD, defined as a ≥ 75% reduction in size of necrotic collection (in any axis) on CT and clinical resolution of sepsis or organ dysfunction. The primary safety endpoint was a composite of major complications or death during follow-up. Six-month postdischarge follow-up was available. Results Between July 18, 2018, and November 12, 2020, we screened 95 patients with necrotizing pancreatitis; of these, 21 iWONde patients (mean [SD] age, 42.9 [11.7] years; 10 [48%] women) were finally enrolled. The primary efficacy endpoint was achieved by most participants (14/21, 67%). No participants required repeated interventions. The primary safety endpoint occurred in six patients (29%). Except one in-hospital death attributable to repeated intra-abdominal hemorrhage, others were discharged without any major complication. Conclusions The VARTD approach appears to have a reasonable efficacy with acceptable complication rates and thus might be an option for improving clinical management of iWONde. Trial registration This study is registered with Chinese Clinical Trial Registry (chictr.org.cn number, ChiCTR1800016950).

Keywords